46.20 0.00 (0.00%)
Pre-Market: 8:28AM EDT
|Bid||46.20 x 2200|
|Ask||46.64 x 800|
|Day's Range||44.29 - 46.46|
|52 Week Range||16.90 - 53.70|
|Beta (3Y Monthly)||3.29|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
When you think of medical devices stocks, you don’t think of cloud-connected watches. You want to invest in more prosaic companies, large and small, which offer discrete devices for specific conditions, with Food and Drug Administration (FDA) approvals and positive clinical trials. The long-term prognosis for medical devices is good, but many companies need to deal with short-term problems to get there, so look for strength – financial strength or strength within a winning niche – when you shop for investments.
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as NovoCure Limited (NASDAQ:NVCR) with a market-capitalization of US$4.36b, rarely draw their attention. However, history shows that overlookedRead More...
Easily the biggest trend in investing has to be healthcare stocks. From rising and aging populations in the developed world to new middle-class consumers gaining access to healthcare for the first time in emerging markets, healthcare demand is only getting bigger by the day. All in all, the combination of the two factors makes the medical device stocks some of best plays in all of healthcare.
On September 6, NovoCure (NVCR) stock rose 5.3% to reach $45.40 compared to the previous day’s close of $43.10. Also, on September 6, NovoCure hit its 52-week high of $46.73. Its closing price for the day represents ~182% growth from its 52-week low of $16.10 on October 13, 2017.
This year, more than 14,000 people in the U.S. will be diagnosed with the same kind of brain cancer that killed Senator John McCain, glioblastoma multiforme, or GBM.
NovoCure’s (NVCR) net financial expenses increased from $2.18 million in the second quarter of 2017 to $2.86 million in the second quarter. NovoCure’s income tax expenses also increased from $3.46 million in the second quarter of 2017 to $5.56 million in the second quarter.
NovoCure (NVCR) is mainly engaged in developing and bringing tumor treating fields for solid tumors to the market. The company’s first tumor treating fields delivery system, Optune, is targeted to treat adult patients with glioblastoma. Tumor treating fields use electric fields tuned to certain frequencies to disrupt solid tumor cancer cell division.
NovoCure (NVCR) generated revenues of $61.51 million in the second quarter—compared to $38.38 million in the second quarter of 2017. The growth was also driven by NovoCure’s initial launch efforts in Japan. NovoCure incurred a cost of revenues of $19.83 million in the second quarter—compared to $13.15 million in the second quarter of 2017.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Canopy Growth Corp (NYSE: CGC ) stock gained more ...
NovoCure (NVCR) released its second-quarter results on July 26. In the second quarter, NovoCure continued to see steady growth in patient prescriptions for new glioblastoma diagnosis. NovoCure reported a net loss of $15.51 million in the second quarter—compared to a net loss of $21.17 million in the second quarter of 2017.
NovoCure (NVCR) is expected to incur SG&A (selling, general, and administrative) expenses of $35.4 million in the second quarter, compared with $31.38 million in the second quarter of 2017, an increase of 12.8%. NovoCure’s R&D (research and development) expenses are expected to increase 47.06% from $9.37 million in the second quarter of 2017 to $13.78 million in the second quarter. NovoCure’s total operating expenses are expected to increase 18.1% from $40.75 million in the second quarter of 2017 to $48.13 million in the second quarter.
NovoCure (NVCR) is expected to report its second-quarter earnings on July 26. In this series, we’ll look at the company’s top-line, operational, and bottom-line performance expected by analysts for the second quarter. We’ll also look at analysts’ recommendations and the performance of NovoCure stock so far this year.
Batting first and playing RF, we have GDS Holdings Ltd. (NASDAQ: GDS). GDS is one of the leading carrier-neutral data center solutions providers in China, and the growing demand for its services has led to impressive growth.
To receive further updates on this Novocure Ltd (NASDAQ:NVCR) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of Power Options Weekly today.
NovoCure Limited made a small base pattern in 2016 and started a strong rally in 2017 and moving up four-fold from its 2017 nadir. Let's review the charts and indicators of NVCR to see what the prospects look like for this company.
Jim Cramer zooms through his take on callers' favorite stocks and lists his top picks in the cybersecurity space.
Shares retreat after the company releases details about an upcoming phase 3 trial. Should investors be worried, or is this just market noise?